Aktiia, a healthcare technology company, has achieved CE mark approval in Europe for its CALFREE technology, which allows for calibration-free blood pressure monitoring using optical sensors in smartwatches and smartphone cameras. This advancement enables the integration of medical-grade blood pressure monitoring into consumer devices.
Dr. Josep Sola, CTO and cofounder of Aktiia, highlighted the significant impact of this technology, which can transform common smart devices into medical-grade BP monitors, facilitating large-scale hypertension diagnosis and management. This development marks a major disruption in the wearable and mobile industries.
Founded in 2018 as a spin-out from the Swiss R&D center CSEM, Aktiia already offers a wrist-worn optical blood pressure monitoring device that provides continuous data on blood pressure, heart rate, and activity. Initially launched in 2021, their system required monthly calibration.
Aktiia has built comprehensive blood pressure models using data from over 70,000 users and has secured substantial funding, including $30 million in a recent round in February 2024. Previous funding includes $6.1 million and $17.5 million in Series A funding rounds.
Click here to read the original news story.